AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Trend
-9.3% vs SMA 50 · -6.4% vs SMA 200
Momentum
Volume distribution is neutral or leaning toward distribution. No compelling squeeze setup based on current money flow data.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $493.2B $460.9B–$525.5B | — | $142.05 | — | ±9% | Low1 |
FY2025 | $445.3B $416.2B–$474.5B | ▼ -9.7% | $98.68 | ▼ -30.5% | ±9% | Low1 |
FY2026(current) | $564.3B $532.8B–$595.9B | ▲ +26.7% | $1187.50 | ▲ +1103.4% | ±9% | Low2 |
Dividend per payment — last 8 periods
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…

Inversiones y Representaciones Sociedad Anónima is the leading real estate development firm in Argentina.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
IRS◀ | $13.97 | -1.41% | $1.1B | 3.8 | +708.8% | 2233.7% | 1500 |
| $396.06 | +0.57% | $2.1T | 28.7 | +3296.8% | 4510.0% | 1500 | |
| $91.86 | +2.89% | $318.3B | 14.0 | +318.8% | 1510.7% | 1500 | |
| $131.91 | +1.13% | $306.2B | 22.6 | +586.3% | 1305.9% | 1500 | |
| $187.37 | +1.17% | $290.5B | 28.1 | +862.9% | 1745.9% | 1500 | |
| $147.85 | +3.44% | $282.1B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $90.67 | +1.98% | $256.7B | 14.5 | -591.0% | 668.4% | 1500 | |
| Sector avg | — | +1.39% | — | 19.0 | +825.7% | 2077.0% | 1500 |